Samsung Bioepis, a Korean-based biopharmaceutical company, announced on Nov. 20, 2017 that its biosimilar, Ontruzant, which references Roche s Herceptin (trastuzumab), has received European regulatory approval for the treatment of early breast cancer, metastatic breast cancer, and metastaticOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.